In its 23rd year the World Vaccine Congress Europe is set to be one of our biggest and most exciting events. We will be bringing experts from the whole value chain together in one place for discussion and networking. In attendance this year are some hugely exciting start-ups, who look forward to meeting you.
If you are interested in joining the start-ups below, make an application here.
If your application is successful you will receive:
- 1m wall space in the heart of the exhibition as part of our Start-up Zone
- 2 full passes to the conference and exhibition
- Branding and marketing on our event website and other marketing materials
- Access to our networking portal where on site meetings can be arranged with our attendees
To find out who is already signed up, read on!
a biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. It is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in this field.
Green Elephant Biotech:
a start-up founded in 2021 by Dr Joel Eichmann and Felix Wollenhaupt in Giessen, Germany. The core idea is to reduce CO2 emissions of single-use plastics within the biotech and pharma industry. The company enables the production of sophisticated therapeutics and vaccines through efficient and scalable cell cultivation devices and consumables while using plant-based materials.
VAX-ID, the heart of the Idevax company, is an award-winning patented drug delivery device suited for intradermal injection. This can be preconfigured with a 32G needle as well as with a 27G needle to allow for different applications, with a penetration depth of 0.85mm and 1.2mm respectively. The device is suited for accurate drug delivery of therapeutic, prophylactic, and allergy drugs and vaccines in the dermal layer of the skin.
an emerging start-up founded in 2018 by a team of life science, cybersecurity, and digital innovation experts, which aims to revolutionise Healthcare through an innovative digital simulation platform, where complex computational models run in an easy and cost-effective way to hyper-accelerate drug and medical device development. Offering Pharma and MedTech companies state-of-the-art simulation tools, it hopes to increase the quality of life of millions of patients by allowing cheaper treatments and bringing innovating drugs and medical devices to the market faster.
MyLife Technologies BV:
developed a platform technology based on ceramic, nanoporous MicroNeedle Arrays (npMNA), which can be used for dermal delivery in a wide range of drugs. In general, the npMNA-patch technology could provide an attractive alternative for specific parenteral formulations, oral dosage forms, or nasal delivery forms.
created 4 years ago. It is a spin-off of the Bellvitge Biomedical Research Institute, Barcelona, Spain, aiming to provide health solutions by removing specific harmful antibodies. The company owns a battery of backbones to which different antigens are attached. The intravenous or subcutaneous injection of the compound removes those circulating antibodies that bind to the attached antigen without any toxic effect or generation of immunity against the composite. In addition, the molecule also binds to the B-cells producing the antibodies, reducing the production of new ones. RemAb Therapeutics is developing a compound to remove anti-PEG antibodies and prevent reactogenicity after vaccination.
developing next-generation bacterial vaccines using a platform technology based on genome-wide association studies. The lead programme, RVX-001, is focused on development of a vaccine targeted at Streptococcus pneumoniae, one of the leading causes of infectious diseases around the world. Supported by research funding ReNewVax Ltd has successfully developed a vaccine formulation that addresses the limitations of existing pneumococcal vaccines.
founded in 2016, in Bangkok, Thailand, the ambition is to not only perfect silk proteins extraction but to design, engineer, and offer industry-defining products around silk proteins and associated innovative technologies. From the early days of extracting sericin from silk waste to formulate cosmetic creams and serums it spread its wings to Europe with new headquarters in Barcelona where it has established a strong link with the biotech, pharmaceutical, and cosmetic ecosystem.
Stone Cold Systems:
Stone Cold Systems (SCS) is transforming the cold chain for vaccines by delivering super modern, connected devices that provide actionable, real-time data to secure and optimise the supply chain for safe vaccinations worldwide. The main innovation consists of transportable vaccine refrigerators, purpose built for enabling mobile vaccination campaigns to reach underserved communities. SCS combines state-of-the-art communications technologies with proven thermal electric cooling, powered by lithium-ion batteries and controlled by proprietary hybrid charging algorithms. This combination of functionality into one, easy-to-use portable device is the innovative and bold solution needed to fundamentally improve vaccination campaigns worldwide.
Two Oceans in Health (2OiH):
a Dominican global health research enterprise, founded and led by recognised public health scientists. It incorporates top-level academic backgrounds and methodological rigour, with decades of research experience focused on different levels of the Dominican health system, clinical research, and related medical education activities. Since its foundation in 2018, the 2OiH team has conducted a large body of studies based on different research methodologies. The team has also participated in important local and international clinical research, generating break-through evidence to support Covid-19 response and decision-making.
a small enterprise with high ambitions, born as a result of work on research projects carried out at the Department of Recombinant Vaccines at the Intercollegiate Faculty of Biotechnology of the University of Gdansk and the Medical University of Gdansk. It works on innovative vaccine development platforms based on virus-like particles, suitable for the production of prophylactic vaccines against infectious diseases in humans and animals and therapeutic vaccines in cancer. It also conducts research and provides services in the field of next generation sequencing.